AACR and Millennium Partner to Offer Two New Grant Opportunities for Lymphoma Research and Prostate Cancer Research
November 27, 2012
The call for applications is open now through Jan. 7, 2013.
PHILADELPHIA — The American Association for Cancer Research and Millennium: The Takeda Oncology Company are pleased to announce a new partnership and call for applications for two grant opportunities to support lymphoma and prostate cancer research.
The 2013 AACR-Millennium Fellowship in Lymphoma Research and the 2013 AACR-Millennium Fellowship in Prostate Cancer Research will each provide young cancer researchers with $55,000 over one year.
“The AACR is very proud to collaborate with Millennium and provide additional fellowship opportunities to promising young investigators who have strong potential to become productive and successful independent cancer researchers,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “As we add these new fellowships to the AACR’s growing grants portfolio, we know they will aid in filling the gaps in the areas of lymphoma and prostate cancer, where more research is greatly needed.”
“At Millennium we’re very excited to partner with the AACR to increase the educational opportunities for young researchers in the area of oncology,” said Karen Ferrante, M.D., chief medical officer at Millennium. “In our efforts to make a dramatic impact on cancer therapeutics, we are dedicated to a strong partnership with the AACR and the oncology community. As leaders in the biopharmaceutical industry we’re very proud to be helping develop the next group of young scientists who will share in that effort.”
Qualified applicants must have a doctoral degree, be in the first five years of their postdoctoral or clinical research fellowship at the start of the grant term and work under the auspices of a mentor at an academic, medical or research institution within the United States. AACR members and nonmembers are eligible to apply; however, nonmembers must submit an application for AACR associate membership. Proposed mentored cancer research projects must have direct applicability and relevance to either lymphoma research or prostate cancer research.
Young investigators who are interested in applying can click here
for additional details. Applications must be submitted to the AACR by noon ET on Monday, Jan. 7, 2013, using the proposalCENTRAL website
. A hard copy with original signatures must also be mailed to the AACR at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106, Attn.: Hanna Hopfinger, postmarked no later than Jan. 9. Additional inquires may be directed to email@example.com
Selected recipients will be announced during a grants ceremony at the AACR Annual Meeting
held April 6-10, 2013, in Washington, D.C., and they will also receive a commemorative plaque. The start date for the AACR-Millennium Fellowship in Lymphoma Research and the AACR-Millennium Fellowship in Prostate Cancer Research is July 1, 2013.
The AACR’s research fellowships program was first established in 1996, and to date has distributed more than $6 million in cancer research funding.
# # #
American Association for Cancer Research
Millennium: The Takeda Oncology Company
(617) 444-4456David.Albaugh@MPI.comAbout the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org
. Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.orgAbout Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. (“Takeda”, TSE: 4502) in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com